The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy

BACKGROUND: Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with interferon beta (IFN beta) can develop neutralizing antibodies (NAbs) that reduce treatment efficacy. Several clinical studies explored the association of NAb+ status with increased disease activity. OBJECTIVE: The aim o...

詳細記述

保存先:
書誌詳細
出版年:PLoS One
主要な著者: Paolicelli, Damiano, Iannazzo, Sergio, Santoni, Laura, Iaffaldano, Antonio, Di Lecce, Valentina, Manni, Alessia, Lavolpe, Vito, Tortorella, Carla, D'Onghia, Mariangela, Direnzo, Vita, Puma, Elisa, Trojano, Maria
フォーマット: Artigo
言語:Inglês
出版事項: Public Library of Science 2016
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4938389/
https://ncbi.nlm.nih.gov/pubmed/27390865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0159214
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料